Varicose Vein Treatment Market Analysis By Treatment Mode (Sclerotherapy, Endovenous Ablation, Stripping, Laser, Radiofrequency Ablation), And Segment Forecasts To 2024
The global varicose vein treatment market is expected to reach USD 475 million by 2024, according to a new report by Grand View Research, Inc. The increasing technological advancements coupled with the increased availability of the advanced varicose vein treatment devices and shift towards less-invasive procedures are the contributing factors for the growth of the market.
The huge burden of vascular diseases in Europe and North America and the increasing patient compliance and reliability, growth in healthcare expenditure, and the rapid growth in geriatric population is majorly driving the varicose vein procedure market.
The upward trend in lifestyle disorders, such as increasing obesity, sleep disorders, blood pressure levels, hormonal changes, genetic disorders and pregnancy are the few major factors contributing to the peripheral vascular diseases. Untreated venous insufficiency, such as varicose vein and venous ulcers cause progressive syndromes including chronic veinous insufficiency. In 2015, according to FutSci, chronic veinous insufficiency is widespread and is a socially isolating condition caused in adults. It is the most common disease in the world and is estimated to affect 5% of the population in the Western countries.
Further key findings from the report suggest:
In 2015, the sclerotherapy segment was identified as the most profitable procedure owing to the benefits, such as the requirement of minimal incision and reduced scarring, related to the procedure. Moreover,the following advantages: increased penetration, cost and time efficiency, reduced risk of collateral damage to surrounding tissues, fewer post-operative complications, and painless procedure are the main contributors for the growth of this segment.
The endovenous ablation segment is expected to be the fastest growing segment due to the benefits of short treatment time and improved blood circulation after the procedure. The ClosureFast technique in the endovenous ablation treatment segmenthas gained momentum due to the minimized side effects, potential cost-saving ability, and better patient outcomes.
In 2015, the endovenous chemoablation or chemical sclerosis segment was the most widely used medical procedure among the ablation procedures. Sclerotherapy, intense-pulsed-light therapy, laser ablation, radiofrequency, and ambulatory phlebectomy are the modern techniques that are usedmore oftendue to their less invasive nature.
In 2016, North America held the largest market share due to the increasing incidence rate of varicose and spider vein in the population, favourable reimbursement policies, increased healthcare awareness, government spending, and the rising aesthetic awareness in the region
As of 2016, Europe is characterized by a shift towards less-invasive procedures in treating large varicose veins. It is expected to witness a high growth rate over the forecast period due to the favorable government initiatives and advanced treatment procedures.
The Asia Pacific is expected to register the fastest growth due to factors, such as the improving healthcare infrastructure, the increase in patient awareness level regarding the benefits of early treatment of the varicose veins, and the rising disposable income
Some key players of the market include Quanta Systems S.p.A, Vascular Solutions, Inc., Eufoton S.R.L, Energist Group, Medtronic plc, Dornier MedTech GmbH, Lumenis Ltd., Syneron Medical Ltd., Biolitec AG, and AngioDynamics, Inc.
AngioDynamics, Inc. and MerzPharma GmbH & Co. KGaAin North America established a multi-year relationship to market Asclera for patients with peripheral vascular diseases.In the U.S,.MerzPharma GmbH & Co. KGaAserves as the exclusive distributor of the Asclera Injection. Asclera is approved for the treatment of spider and reticular veins, which showed good improvement in 95% of the patients treated with asclera.
In 2016, Medtronic plc acquired Italian hemodialysis player Bellco, Inc.This acquisition is projected to enable the medical device giant to gain market position in newly formed renal care solution business.
In 2015, Medtronic plc acquired Covidien plc with the objective to move into the additional therapeutic areas, such as chronic venous insufficiency. Covidien plc markets the Venefit procedure that uses radiofrequency energy and minimally invasive radiofrequency ablation to treat the disease.
The huge burden of vascular diseases in Europe and North America and the increasing patient compliance and reliability, growth in healthcare expenditure, and the rapid growth in geriatric population is majorly driving the varicose vein procedure market.
The upward trend in lifestyle disorders, such as increasing obesity, sleep disorders, blood pressure levels, hormonal changes, genetic disorders and pregnancy are the few major factors contributing to the peripheral vascular diseases. Untreated venous insufficiency, such as varicose vein and venous ulcers cause progressive syndromes including chronic veinous insufficiency. In 2015, according to FutSci, chronic veinous insufficiency is widespread and is a socially isolating condition caused in adults. It is the most common disease in the world and is estimated to affect 5% of the population in the Western countries.
Further key findings from the report suggest:
In 2015, the sclerotherapy segment was identified as the most profitable procedure owing to the benefits, such as the requirement of minimal incision and reduced scarring, related to the procedure. Moreover,the following advantages: increased penetration, cost and time efficiency, reduced risk of collateral damage to surrounding tissues, fewer post-operative complications, and painless procedure are the main contributors for the growth of this segment.
The endovenous ablation segment is expected to be the fastest growing segment due to the benefits of short treatment time and improved blood circulation after the procedure. The ClosureFast technique in the endovenous ablation treatment segmenthas gained momentum due to the minimized side effects, potential cost-saving ability, and better patient outcomes.
In 2015, the endovenous chemoablation or chemical sclerosis segment was the most widely used medical procedure among the ablation procedures. Sclerotherapy, intense-pulsed-light therapy, laser ablation, radiofrequency, and ambulatory phlebectomy are the modern techniques that are usedmore oftendue to their less invasive nature.
In 2016, North America held the largest market share due to the increasing incidence rate of varicose and spider vein in the population, favourable reimbursement policies, increased healthcare awareness, government spending, and the rising aesthetic awareness in the region
As of 2016, Europe is characterized by a shift towards less-invasive procedures in treating large varicose veins. It is expected to witness a high growth rate over the forecast period due to the favorable government initiatives and advanced treatment procedures.
The Asia Pacific is expected to register the fastest growth due to factors, such as the improving healthcare infrastructure, the increase in patient awareness level regarding the benefits of early treatment of the varicose veins, and the rising disposable income
Some key players of the market include Quanta Systems S.p.A, Vascular Solutions, Inc., Eufoton S.R.L, Energist Group, Medtronic plc, Dornier MedTech GmbH, Lumenis Ltd., Syneron Medical Ltd., Biolitec AG, and AngioDynamics, Inc.
AngioDynamics, Inc. and MerzPharma GmbH & Co. KGaAin North America established a multi-year relationship to market Asclera for patients with peripheral vascular diseases.In the U.S,.MerzPharma GmbH & Co. KGaAserves as the exclusive distributor of the Asclera Injection. Asclera is approved for the treatment of spider and reticular veins, which showed good improvement in 95% of the patients treated with asclera.
In 2016, Medtronic plc acquired Italian hemodialysis player Bellco, Inc.This acquisition is projected to enable the medical device giant to gain market position in newly formed renal care solution business.
In 2015, Medtronic plc acquired Covidien plc with the objective to move into the additional therapeutic areas, such as chronic venous insufficiency. Covidien plc markets the Venefit procedure that uses radiofrequency energy and minimally invasive radiofrequency ablation to treat the disease.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Research methodology
1.2. Research scope &assumption
1.3. List of data sources
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Varicose Vein Treatment- Industry snapshot and key buying criteria, 2013 - 2024
CHAPTER 3. VARICOSE VEIN TREATMENT OUTLOOK
3.1. Varicose vein treatment segmentation
3.2. Varicose vein treatment size and growth prospects, 2013 - 2024
3.3. Varicose vein treatment: Market dynamics
3.3.1. Market driver analysis
3.3.1.1. Shift towards less-invasive treatment procedures
3.3.1.2. Advanced Varicose vein treatment devices
3.3.1.3. Growth in ageing population
3.3.2. Market restraint analysis
3.3.2.1. Risk factors pertaining to varicose vein treatment
3.4. Key opportunities prioritized
3.5. Industry analysis - Porter's
3.6. Varicose vein treatment competitive landscape
3.6.1. Competitive landscape: Market position analysis (based on products, regional presence, and strategic initiatives)
3.7. Varicose vein treatment PESTEL analysis, 2015
3.8. Varicose Vein Treatment: Future aspects
CHAPTER 4. VARICOSE VEIN TYPEOUTLOOK
4.1. Varicose vein treatment share by type, 2013 & 2024
4.2. Sclerotherapy
4.2.1. Sclerotherapy market estimates, 2013 - 2015 (USD Million)
4.2.2. Sclerotherapy market forecasts, 2016 - 2024 (USD million)
4.3. Endovenous ablation
4.3.1. Endovenous ablation market estimates, 2013 - 2015 (USD Million)
4.3.2. Endovenous ablation market forecasts, 2016 - 2024 (USD Million)
4.3.2.1. Radio frequency ablation market estimates, 2013 - 2015 (USD Million)
4.3.2.2. Radio frequency ablation market forecasts, 2016 - 2024 (USD Million)
4.3.2.3. Laser ablation market estimates, 2013 - 2015 (USD Million)
4.3.2.4. Laser ablation market estimates, 2013 - 2015 (USD Million)
4.4. Stripping
4.4.1. Stripping market estimates, 2013 - 2015 (USD Million)
4.4.2. Stripping market forecasts, 2016 - 2024 (USD million)
CHAPTER 5. VARICOSE VEIN TREATMENT REGIONALOUTLOOK
5.1. North America
5.1.1. Varicose vein treatment market estimates, by type 2013 - 2015 (USD Million)
5.1.2. Varicose vein treatment market forecasts, by type, 2016 - 2024 (USD Million)
5.1.2.1. U.S.
5.1.2.1.1. Varicose vein treatment markete stimates, 2013 - 2015 (USD Million)
5.1.2.1.2. Varicose vein treatment market forecasts, 2016 - 2024 (USD Million)
5.1.2.2. Canada
5.1.2.2.1. Varicose vein treatment markete stimates, 2013 - 2015 (USD Million)
5.1.2.2.2. Varicose vein treatment market forecasts, 2016 - 2024 (USD Million)
5.2. Europe
5.2.1. Varicose vein treatment market estimates, by type, 2013 - 2015 (USD Million)
5.2.2. Varicose vein treatment market forecasts, by type, 2016 - 2024 (USD Million)
5.2.2.1. UK
5.2.2.1.1. Varicose vein treatment markete stimates, 2013 - 2015 (USD Million)
5.2.2.1.2. Varicose vein treatment market forecasts, 2016 - 2024 (USD Million)
5.2.2.2. Germany
5.2.2.2.1. Varicose vein treatment markete stimates, 2013 - 2015 (USD Million)
5.2.2.2.2. Varicose vein treatment market forecasts, 2016 - 2024 (USD Million)
5.2.2.3. France
5.2.2.3.1. Varicose vein treatment markete stimates, 2013 - 2015 (USD Million)
5.2.2.3.2. Varicose vein treatment market forecasts, 2016 - 2024 (USD Million)
5.3. Asia Pacific
5.3.1. Varicose vein treatment market estimates, by type 2013 - 2015 (USD Million)
5.3.2. Varicose vein treatment market forecasts, by type, 2016 - 2024 (USD Million)
5.3.2.1. India
5.3.2.1.1. Varicose vein treatment markete stimates, 2013 - 2015 (USD Million)
5.3.2.1.2. Varicose vein treatment market forecasts, 2016 - 2024 (USD Million)
5.3.2.2. China
5.3.2.2.1. Varicose vein treatment markete stimates, 2013 - 2015 (USD Million)
5.3.2.2.2. Varicose vein treatment market forecasts, 2016 - 2024 (USD Million)
5.3.2.3. Japan
5.3.2.3.1. Varicose vein treatment markete stimates, 2013 - 2015 (USD Million)
5.3.2.3.2. Varicose vein treatment market forecasts, 2016 - 2024 (USD Million)
5.4. Latin America
5.4.1. Varicose vein treatment market estimates, by type, 2013 - 2015 (USD Million)
5.4.2. Varicose vein treatment forecasts, by type, 2016 - 2024 (USD Million)
5.4.2.1. Mexico
5.4.2.1.1. Varicose vein treatment markete stimates, 2013 - 2015 (USD Million)
5.4.2.1.2. Varicose vein treatment market forecasts, 2016 - 2024 (USD Million)
5.4.2.2. Brazil
5.4.2.2.1. Varicose vein treatment markete stimates, 2013 - 2015 (USD Million)
5.4.2.2.2. Varicose vein treatment market forecasts, 2016 - 2024 (USD Million)
5.5. MEA
5.5.1. Varicose vein treatment market estimates, by type, 2013-2015 (USD Million)
5.5.2. Varicose vein treatment market forecasts, by type, 2016 - 2024 (USD Million)
5.5.2.1. South Africa
5.5.2.1.1. Varicose vein treatment markete stimates, 2013 - 2015 (USD Million)
5.5.2.1.2. Varicose vein treatment market forecasts, 2016 - 2024 (USD Million)
CHAPTER 6. COMPETITIVELANDSCAPE
6.1. Medtronic plc
6.1.1. Company Overview
6.1.2. Financial Performance
6.1.3. Product Benchmarking
6.1.4. Strategic Initiatives
6.2. Angio Dynamics, Inc.
6.2.1. Company Overview
6.2.2. Financial Performance
6.2.3. Product Benchmarking
6.2.4. Strategic Initiatives
6.3. Biolitec AG
6.3.1. Company Overview
6.3.2. Financial Performance
6.3.3. Product Benchmarking
6.3.4. Strategic Initiatives
6.4. Syneron Medical Ltd.
6.4.1. Company Overview
6.4.2. Financial Performance
6.4.3. Product Benchmarking
6.4.4. Strategic Initiatives
6.5. Lumenis Ltd.
6.5.1. Company Overview
6.5.2. Financial Performance
6.5.3. Product Benchmarking
6.5.4. Strategic Initiatives
6.6. Dornier MedTech GmbH
6.6.1. Company Overview
6.6.2. Financial Performance
6.6.3. Product Benchmarking
6.6.4. Strategic Initiatives
6.7. Energist Group
6.7.1. Company Overview
6.7.2. Financial Performance
6.7.3. Product Benchmarking
6.7.4. Strategic Initiatives
6.8. Eufoton S. R.L.
6.8.1. Company Overview
6.8.2. Financial Performance
6.8.3. Product Benchmarking
6.8.4. Strategic Initiatives
6.9. Vascular Solutions, Inc.
6.9.1. Company Overview
6.9.2. Financial Performance
6.9.3. Product Benchmarking
6.9.4. Strategic Initiatives
6.10. Quanta Systems S.p.A.
6.10.1. Company Overview
6.10.2. Financial Performance
6.10.3. Product Benchmarking
6.10.4. Strategic Initiatives
1.1. Research methodology
1.2. Research scope &assumption
1.3. List of data sources
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Varicose Vein Treatment- Industry snapshot and key buying criteria, 2013 - 2024
CHAPTER 3. VARICOSE VEIN TREATMENT OUTLOOK
3.1. Varicose vein treatment segmentation
3.2. Varicose vein treatment size and growth prospects, 2013 - 2024
3.3. Varicose vein treatment: Market dynamics
3.3.1. Market driver analysis
3.3.1.1. Shift towards less-invasive treatment procedures
3.3.1.2. Advanced Varicose vein treatment devices
3.3.1.3. Growth in ageing population
3.3.2. Market restraint analysis
3.3.2.1. Risk factors pertaining to varicose vein treatment
3.4. Key opportunities prioritized
3.5. Industry analysis - Porter's
3.6. Varicose vein treatment competitive landscape
3.6.1. Competitive landscape: Market position analysis (based on products, regional presence, and strategic initiatives)
3.7. Varicose vein treatment PESTEL analysis, 2015
3.8. Varicose Vein Treatment: Future aspects
CHAPTER 4. VARICOSE VEIN TYPEOUTLOOK
4.1. Varicose vein treatment share by type, 2013 & 2024
4.2. Sclerotherapy
4.2.1. Sclerotherapy market estimates, 2013 - 2015 (USD Million)
4.2.2. Sclerotherapy market forecasts, 2016 - 2024 (USD million)
4.3. Endovenous ablation
4.3.1. Endovenous ablation market estimates, 2013 - 2015 (USD Million)
4.3.2. Endovenous ablation market forecasts, 2016 - 2024 (USD Million)
4.3.2.1. Radio frequency ablation market estimates, 2013 - 2015 (USD Million)
4.3.2.2. Radio frequency ablation market forecasts, 2016 - 2024 (USD Million)
4.3.2.3. Laser ablation market estimates, 2013 - 2015 (USD Million)
4.3.2.4. Laser ablation market estimates, 2013 - 2015 (USD Million)
4.4. Stripping
4.4.1. Stripping market estimates, 2013 - 2015 (USD Million)
4.4.2. Stripping market forecasts, 2016 - 2024 (USD million)
CHAPTER 5. VARICOSE VEIN TREATMENT REGIONALOUTLOOK
5.1. North America
5.1.1. Varicose vein treatment market estimates, by type 2013 - 2015 (USD Million)
5.1.2. Varicose vein treatment market forecasts, by type, 2016 - 2024 (USD Million)
5.1.2.1. U.S.
5.1.2.1.1. Varicose vein treatment markete stimates, 2013 - 2015 (USD Million)
5.1.2.1.2. Varicose vein treatment market forecasts, 2016 - 2024 (USD Million)
5.1.2.2. Canada
5.1.2.2.1. Varicose vein treatment markete stimates, 2013 - 2015 (USD Million)
5.1.2.2.2. Varicose vein treatment market forecasts, 2016 - 2024 (USD Million)
5.2. Europe
5.2.1. Varicose vein treatment market estimates, by type, 2013 - 2015 (USD Million)
5.2.2. Varicose vein treatment market forecasts, by type, 2016 - 2024 (USD Million)
5.2.2.1. UK
5.2.2.1.1. Varicose vein treatment markete stimates, 2013 - 2015 (USD Million)
5.2.2.1.2. Varicose vein treatment market forecasts, 2016 - 2024 (USD Million)
5.2.2.2. Germany
5.2.2.2.1. Varicose vein treatment markete stimates, 2013 - 2015 (USD Million)
5.2.2.2.2. Varicose vein treatment market forecasts, 2016 - 2024 (USD Million)
5.2.2.3. France
5.2.2.3.1. Varicose vein treatment markete stimates, 2013 - 2015 (USD Million)
5.2.2.3.2. Varicose vein treatment market forecasts, 2016 - 2024 (USD Million)
5.3. Asia Pacific
5.3.1. Varicose vein treatment market estimates, by type 2013 - 2015 (USD Million)
5.3.2. Varicose vein treatment market forecasts, by type, 2016 - 2024 (USD Million)
5.3.2.1. India
5.3.2.1.1. Varicose vein treatment markete stimates, 2013 - 2015 (USD Million)
5.3.2.1.2. Varicose vein treatment market forecasts, 2016 - 2024 (USD Million)
5.3.2.2. China
5.3.2.2.1. Varicose vein treatment markete stimates, 2013 - 2015 (USD Million)
5.3.2.2.2. Varicose vein treatment market forecasts, 2016 - 2024 (USD Million)
5.3.2.3. Japan
5.3.2.3.1. Varicose vein treatment markete stimates, 2013 - 2015 (USD Million)
5.3.2.3.2. Varicose vein treatment market forecasts, 2016 - 2024 (USD Million)
5.4. Latin America
5.4.1. Varicose vein treatment market estimates, by type, 2013 - 2015 (USD Million)
5.4.2. Varicose vein treatment forecasts, by type, 2016 - 2024 (USD Million)
5.4.2.1. Mexico
5.4.2.1.1. Varicose vein treatment markete stimates, 2013 - 2015 (USD Million)
5.4.2.1.2. Varicose vein treatment market forecasts, 2016 - 2024 (USD Million)
5.4.2.2. Brazil
5.4.2.2.1. Varicose vein treatment markete stimates, 2013 - 2015 (USD Million)
5.4.2.2.2. Varicose vein treatment market forecasts, 2016 - 2024 (USD Million)
5.5. MEA
5.5.1. Varicose vein treatment market estimates, by type, 2013-2015 (USD Million)
5.5.2. Varicose vein treatment market forecasts, by type, 2016 - 2024 (USD Million)
5.5.2.1. South Africa
5.5.2.1.1. Varicose vein treatment markete stimates, 2013 - 2015 (USD Million)
5.5.2.1.2. Varicose vein treatment market forecasts, 2016 - 2024 (USD Million)
CHAPTER 6. COMPETITIVELANDSCAPE
6.1. Medtronic plc
6.1.1. Company Overview
6.1.2. Financial Performance
6.1.3. Product Benchmarking
6.1.4. Strategic Initiatives
6.2. Angio Dynamics, Inc.
6.2.1. Company Overview
6.2.2. Financial Performance
6.2.3. Product Benchmarking
6.2.4. Strategic Initiatives
6.3. Biolitec AG
6.3.1. Company Overview
6.3.2. Financial Performance
6.3.3. Product Benchmarking
6.3.4. Strategic Initiatives
6.4. Syneron Medical Ltd.
6.4.1. Company Overview
6.4.2. Financial Performance
6.4.3. Product Benchmarking
6.4.4. Strategic Initiatives
6.5. Lumenis Ltd.
6.5.1. Company Overview
6.5.2. Financial Performance
6.5.3. Product Benchmarking
6.5.4. Strategic Initiatives
6.6. Dornier MedTech GmbH
6.6.1. Company Overview
6.6.2. Financial Performance
6.6.3. Product Benchmarking
6.6.4. Strategic Initiatives
6.7. Energist Group
6.7.1. Company Overview
6.7.2. Financial Performance
6.7.3. Product Benchmarking
6.7.4. Strategic Initiatives
6.8. Eufoton S. R.L.
6.8.1. Company Overview
6.8.2. Financial Performance
6.8.3. Product Benchmarking
6.8.4. Strategic Initiatives
6.9. Vascular Solutions, Inc.
6.9.1. Company Overview
6.9.2. Financial Performance
6.9.3. Product Benchmarking
6.9.4. Strategic Initiatives
6.10. Quanta Systems S.p.A.
6.10.1. Company Overview
6.10.2. Financial Performance
6.10.3. Product Benchmarking
6.10.4. Strategic Initiatives
LIST OF TABLES
Table 1 Varicose vein treatment Market - Industry Snapshot &Key Buying Criteria, 2012 - 2022
Table 2 Global Varicose vein treatment market, by region, 2013 - 2024 (USD Million)
Table 3 Global Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 6 Varicose vein treatment - Key market driver analysis
Table 7 Varicose vein treatment - Key market restraint analysis
Table 8 North America Varicose vein treatment market, by country, 2013 - 2024 (USD Million)
Table 9 North America Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 10 U.S. Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 11 Canada Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 12 Europe Varicose vein treatment market, by country, 2013 - 2024 (USD Million)
Table 13 Europe Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 14 UK Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 15 Germany Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 16 France Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 17 Asia Pacific Varicose vein treatment market, by country, 2013 - 2024 (USD Million)
Table 18 AsiaPacific Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 19 Japan Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 20 China Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 21 India Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 22 Latin America Varicose vein treatment market, by country, 2013 - 2024 (USD Million)
Table 23 Latin America Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 24 Brazil Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 25 Mexico Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 26 MEA Varicose vein treatment market, by country, 2013 - 2024 (USD Million)
Table 27 MEA Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 28 South Africa Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 1 Varicose vein treatment Market - Industry Snapshot &Key Buying Criteria, 2012 - 2022
Table 2 Global Varicose vein treatment market, by region, 2013 - 2024 (USD Million)
Table 3 Global Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 6 Varicose vein treatment - Key market driver analysis
Table 7 Varicose vein treatment - Key market restraint analysis
Table 8 North America Varicose vein treatment market, by country, 2013 - 2024 (USD Million)
Table 9 North America Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 10 U.S. Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 11 Canada Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 12 Europe Varicose vein treatment market, by country, 2013 - 2024 (USD Million)
Table 13 Europe Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 14 UK Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 15 Germany Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 16 France Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 17 Asia Pacific Varicose vein treatment market, by country, 2013 - 2024 (USD Million)
Table 18 AsiaPacific Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 19 Japan Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 20 China Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 21 India Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 22 Latin America Varicose vein treatment market, by country, 2013 - 2024 (USD Million)
Table 23 Latin America Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 24 Brazil Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 25 Mexico Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 26 MEA Varicose vein treatment market, by country, 2013 - 2024 (USD Million)
Table 27 MEA Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
Table 28 South Africa Varicose vein treatment market, by type, 2013 - 2024 (USD Million)
